Time to Replace Assessment of Liver Histology with MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease

Gastroenterology

Volumn 150, Issue 1, 2016, Pages 7-10

  Byrne, Christopher D ^a   Targher, Giovanni ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Department of Pediatrics   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OBETICHOLIC ACID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; END STAGE LIVER DISEASE; FAT CONTENT; FIBROGENESIS; FOOD AND DRUG ADMINISTRATION; HEPATOGRAPHY; HUMAN; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIPID STORAGE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; WEIGHT CHANGE; AGED; CHRONIC DISEASE; DIAGNOSTIC IMAGING; FEMALE; FORECASTING; GREAT BRITAIN; IMMUNOHISTOCHEMISTRY; LIVER FAILURE; MALE; MIDDLE AGED; NEEDLE BIOPSY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRENDS;

AGED; BIOPSY, NEEDLE; CHRONIC DISEASE; DIAGNOSTIC IMAGING; FEMALE; FORECASTING; GREAT BRITAIN; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER FAILURE; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84952690391     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.11.016     Document Type: Editorial

References (21)

1. C.D. Byrne, and G. Targher NAFLD: a multisystem disease J Hepatol 62 2015 S47 S64
2. R.J. Wong, M. Aguilar, R. Cheung, and et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States Gastroenterology 148 2015 547 555
3. K.C. Sung, W.S. Jeong, S.H. Wild, and et al. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes Diabetes Care 35 2012 717 722
4. K.C. Sung, S.H. Wild, and C.D. Byrne Resolution of fatty liver and risk of incident diabetes J Clin Endocrinol Metab 98 2013 3637 3643
5. H. Yamazaki, T. Tsuboya, K. Tsuji, and et al. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes mellitus Diabetes Care 38 2015 1673 1679
6. Q.M. Anstee, G. Targher, and C.P. Day Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis Nat Rev Gastroenterol Hepatol 10 2013 330 344
7. E. Scorletti, A.L. West, L. Bhatia, and et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME∗trial J Hepatol 2015 Aug 10 [Epub ahead of print]
8. V. Nobili, G. Bedogni, B. Donati, and et al. The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease J Med Food 16 2013 957 960
9. B. Neuschwander-Tetri, R. Loomba, A. Sanyal, et al. for the NASH Clinical Research Network Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet 385 2015 956 965
10. S. McPherson, T. Hardy, E. Henderson, and et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management J Hepatol 62 2015 1148 1155
11. V.W. Wong, G.L. Wong, P.C. Choi, and et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years Gut 59 2010 969 974
12. R. Pais, F. Charlotte, L. Fedchuk, and et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver J Hepatol 59 2013 550 556
13. S. Singh, A.M. Allen, Z. Wang, and et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies Clin Gastroenterol Hepatol 13 2015 643 654
14. E. Vilar-Gomez, Y. Martinez-Perez, L. Calzadilla-Bertot, and et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis Gastroenterology 149 2015 367 378
15. G. Lassailly, R. Caiazzo, D. Buob, and et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients Gastroenterology 149 2015 379 388
16. M. Noureddin, J. Lam, M.R. Peterson, and et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials Hepatology 58 2013 1930 1940
17. S.B. Reeder Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis Hepatology 58 2013 1877 1880
18. E. Scorletti, L. Bhatia, K.G. McCormick, and et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME study Hepatology 60 2014 1211 1221
19. C.K. Argo, J.T. Patrie, C. Lackner, and et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial J Hepatol 62 2015 190 197
20. R. Loomba, C.B. Sirlin, B. Ang, and et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial) Hepatology 61 2015 1239 1250
21. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389